Changiz Taghibiglou

Dr. Changiz Taghibiglou

University of Saskatchewan
+1
orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 May 2017 in Journal of Alzheimer’s Disease
Verified
Journal Article
Closed access
PDF file
MTMengxi Tang
Mengxi Tang
Changiz TaghibiglouChangiz Taghibiglou
Changiz Taghibiglou
Alzheimer’s disease (AD) is a neurodegenerative disorder of the elderly. As the prevalence of AD rises in the 21st century, there is an urgent need for the development of effective pharmacotherapies. Currently, drug treatments target the symptoms of the disease and do not modify or halt the disease progress. Thus, natural compounds have been investigated for their ability to treat AD. This review examines the efficacy of curcumin, a polyphenol derived from turmeric herb, to treat AD. We summarize the in vivo and in vitro research describing the mechanisms of action in which curcumin modifies AD pathology: curcumin inhibits the formation and promotes the disaggregation of amyloid-β plaques, attenuates the hyperphosphorylation of tau and enhances its clearance, binds copper, lowers cholesterol, modifies microglial activity, inhibits acetylcholinesterase, mediates the insulin signaling pathway, and is an antioxidant. In conclusion, curcumin has the potential to be more efficacious than current treatments. However, its usefulness as a therapeutic agent may be hindered by its low bioavailability. If the challenge of low bioavailability is overcome, curcumin-based medications for AD may be in the horizon.

16 December 2018 in European Journal of Neuroscience
Verified
Journal Article
Closed access
PDF file
JTJoel Tehse
Joel Tehse
Changiz TaghibiglouChangiz Taghibiglou
Changiz Taghibiglou

14 March 2014 in Chemical Biology & Drug Design
Verified
Journal Article
Closed access
PDF file
JSJocelyn Stockwell
Jocelyn Stockwell
NANabiha Abdi
Nabiha Abdi
XLXiaofan Lu
Xiaofan Lu
OMOshin Maheshwari
Oshin Maheshwari
Changiz TaghibiglouChangiz Taghibiglou
Changiz Taghibiglou

1 June 2017 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
SISiqingaowa
Siqingaowa
SSSathiya Sekar
Sathiya Sekar
VGVenkat Gopalakrishnan
Venkat Gopalakrishnan
Changiz TaghibiglouChangiz Taghibiglou
Changiz Taghibiglou

Verified
Journal Article
Open access
PDF file
HMHAJAR MIRANZADEH MAHABADI
HAJAR MIRANZADEH MAHABADI
Changiz TaghibiglouChangiz Taghibiglou
Changiz Taghibiglou
Cellular prion protein (PrPc) is a small glycosylphosphatidylinositol (GPI) anchored protein most abundantly found in the outer leaflet of the plasma membrane (PM) in the central nervous system (CNS). PrPc misfolding causes neurodegenerative prion diseases in the CNS. PrPc interacts with a wide range of protein partners because of the intrinsically disordered nature of the protein’s N-terminus. Numerous studies have attempted to decipher the physiological role of the prion protein by searching for proteins which interact with PrPc. Biochemical characteristics and biological functions both appear to be affected by interacting protein partners. The key challenge in identifying a potential interacting partner is to demonstrate that binding to a specific ligand is necessary for cellular physiological function or malfunction. In this review, we have summarized the intracellular and extracellular interacting partners of PrPc and potential consequences of their binding. We also briefly describe prion disease-related mutations at the end of this review.